MorphoSys AG logo
MorphoSys AG MOR

Annual report 2023
added 12-27-2025

report update icon

MorphoSys AG Balance Sheet 2011-2026 | MOR

Annual Balance Sheet MorphoSys AG

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- 163 M -1.74 M 268 M 8.9 M -5.07 M 6.08 M 81 M 127 M 38.1 M -54.5 M

Long Term Debt

- - - 273 M - 71.5 K 87.8 K 218 K 225 K 252 K 299 K 73.6 K 73.6 K

Long Term Debt Current

3.63 M 7.56 M 3.24 M 3.06 M 2.03 M - - - - - - - -

Total Non Current Liabilities

- - - - 40.2 M 4.47 M 9.03 M 9.84 M 9.87 M 45 M 60.1 M 6.63 M 7.52 M

Total Liabilities

1.98 B 2.24 B 2.31 B 1.04 B 102 M 50.4 M 56.7 M 48.1 M 37.3 M 77.7 M 95.5 M 22.3 M 31.3 M

Deferred Revenue

- - - 86.5 M 1.57 M 794 K 1.39 M 1.23 M 1.99 M 14.1 M 15.3 M 628 K -

Retained Earnings

- - - -158 M -256 M -153 M -97.4 M -27.5 M 32.8 M 17.9 M 20.9 M 7.62 M 5.68 M

Total Assets

2.03 B 2.4 B 2.56 B 1.66 B 496 M 539 M 415 M 464 M 400 M 426 M 448 M 224 M 228 M

Cash and Cash Equivalents

158 M 402 M 123 M 110 M 44.3 M 45.5 M 76.6 M 73.9 M - - - - -

Book Value

49 M 157 M 245 M 621 M 395 M 488 M 359 M 415 M 363 M 349 M 352 M 202 M 197 M

Total Shareholders Equity

- - - 621 M 395 M 488 M 359 M 415 M - - - - -

All numbers in EUR currency

Quarterly Balance Sheet MorphoSys AG

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 39.3 M - - - 42 M - - - 40 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 2.03 B - - - 838 M - - - 40.2 M - - - 4.47 M - - - 9.03 M - - - 9.84 M - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - 2.31 B - - - 1.04 B - - - 102 M - - - 50.4 M - - - 56.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -672 M - - - -158 M - - - -256 M - - - -153 M - - - -97.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 2.56 B - - - 1.66 B - - - 496 M - - - 539 M - - - 415 M - - - 464 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 123 M - - - 110 M - - - 44.3 M - - - 45.5 M - - - 76.6 M - - - 73.9 M - - - 90.9 M - - - - - - - - - - - - - - - - - - -

Book Value

- - - - 245 M - - - 621 M - - - 395 M - - - 488 M - - - 359 M - - - 464 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 245 M - - - 621 M - - - 395 M - - - 488 M - - - 360 M - - - 415 M - - - 363 M - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Balance Sheet is a fundamental financial report of MorphoSys AG, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 2.86 -4.98 % $ 221 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.32 7.79 % $ 7.99 B australiaAustralia
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 10.75 -4.78 % $ 695 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.9 -4.77 % $ 485 M britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 211.51 -0.81 % $ 5 B danmarkDanmark
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.21 3.0 % $ 457 M israelIsrael
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BioVie BioVie
BIVI
$ 1.33 14.66 % $ 1.96 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
$ 0.81 -4.71 % $ 110 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.12 -6.28 % $ 732 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Certara Certara
CERT
$ 8.73 -0.91 % $ 1.4 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 96.21 1.06 % $ 27.2 B germanyGermany
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.13 -2.41 % $ 1.27 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Cellectis S.A. Cellectis S.A.
CLLS
$ 4.77 -1.45 % $ 116 M franceFrance
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.31 -3.12 % $ 136 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 36.68 5.4 % $ 3.79 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 26.99 -0.63 % $ 1.74 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 561.1 -1.2 % $ 42.5 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 3.38 14.41 % $ 41.3 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.75 5.58 % $ 17.3 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 91.61 -0.35 % $ 96.9 B britainBritain
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA